
CanSino Biologics Inc
SSE:688185

CanSino Biologics Inc
EPS (Diluted)
CanSino Biologics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
CanSino Biologics Inc
SSE:688185
|
EPS (Diluted)
-ÂĄ6
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
![]() |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
ÂĄ5
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
![]() |
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
ÂĄ1
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
15%
|
|
![]() |
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
ÂĄ2
|
CAGR 3-Years
19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
CanSino Biologics Inc
Glance View
CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

See Also
What is CanSino Biologics Inc's EPS (Diluted)?
EPS (Diluted)
-6
CNY
Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's EPS (Diluted) amounts to -6 CNY.
What is CanSino Biologics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-46%
Over the last year, the EPS (Diluted) growth was -63%. The average annual EPS (Diluted) growth rates for CanSino Biologics Inc have been -52% over the past three years , -46% over the past five years .